<scp>MEK</scp> inhibition alleviates macrophage overactivation without compromising the efficacy of <scp>CAR</scp> ‐T‐cell therapy
This study presents mitogen-activated protein kinase kinase (MEK) inhibition as a strategy for cytokine release syndrome (CRS) and secondary haemophagocytic lymphohistiocytosis (sHLH) in chimeric antigen receptor (CAR)-T therapy, utilizing MEK's regulatory actions that target macrophage activation, cytokine secretion from both macrophages and CAR-T cells, supported by evidence of unimpaired CAR-T-cell therapeutic efficacy of alleviated CAR-T-related inflammation.
Authors
- Xingbing Wang (ORCID: https://orcid.org/0000-0002-5591-2168)
- Yunfeng Chen (ORCID: https://orcid.org/0000-0002-7534-0021)
- M. W. Wu
- Yuzhu Wang (ORCID: https://orcid.org/0009-0009-3416-316X)
- Li Ding (ORCID: https://orcid.org/0000-0002-2273-1950)
- Qianwen Xu (ORCID: https://orcid.org/0000-0003-0360-7193)
- Sujun Li
- Hui Li
Institutions
- University of Science and Technology of China (CN)
- Anhui University (CN)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2026-02-18
- DOI
- https://doi.org/10.1111/bjh.70364
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00